Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment

Clinical Neurophysiology

Volumn 127, Issue 3, 2016, Pages 1764-1773

  Needham, Merrilee ^a,b,c   Mastaglia, Frank L ^a  

^a MURDOCH UNIVERSITY   (Australia)

^b FIONA STANLEY HOSPITAL   (Australia)

^c UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

Diagnostic criteria; Electrophysiology; Inclusion body myositis; Muscle imaging; Natural history; Phenotype; Treatment

Indexed keywords

5' NUCLEOTIDASE; ALEMTUZUMAB; BIMAGRUMAB; BIOLOGICAL MARKER; ETANERCEPT; FOLLISTATIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

DIAGNOSTIC APPROACH ROUTE; DYSPHAGIA; ELECTROPHYSIOLOGY; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEART DISEASE; HUMAN; INCLUSION BODY MYOSITIS; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMATIC REVIEW; BLOOD; COHORT ANALYSIS; ELECTROMYOGRAPHY; MYOSITIS, INCLUSION BODY; PROCEDURES; TREATMENT OUTCOME;

BIOMARKERS; COHORT STUDIES; ELECTROMYOGRAPHY; HUMANS; MYOSITIS, INCLUSION BODY; TREATMENT OUTCOME;

EID: 85027938990     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2015.12.011     Document Type: Review

References (119)

1. Abdo, W.F., van Mierlo, T., Hengstman, G.J., Schelhaas, H.J., van Engelen, B.G., Verbeek, M.M., Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis. Acta Neuropathol 118:3 (2009), 429–431.
2. Aggarwal, R., Lebiedz-Odrobina, D., Sinha, A., Manadan, A., Case, J.P., Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. J Rheumatol 36:12 (2009), 2711–2714.
3. Alexanderson, H., Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep 14:3 (2012), 244–251.
4. Alexanderson, H., Lundberg, I.E., Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 24:2 (2012), 201–207.
5. Alfano, L.N., Lowes, L.P., Dvorchik, I., Yin, H., Maus, E.G., Flanigan, K.M., et al. The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis. Neuromuscul Disord 24:3 (2014), 222–226.
6. Allenbach, Y., Benveniste, O., Decostre, V., Canal, A., Eymard, B., Herson, S., et al. Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscul Disord 22:11 (2012), 980–986.
7. Allenbach, Y., Chaara, W., Rosenzwajg, M., Six, A., Prevel, N., Mingozzi, F., et al. Th1 response and systemic treg deficiency in inclusion body myositis. PLoS One, 9(3), 2014, e88788.
8. Amato, A.A., Sivakumar, K., Goyal, N., David, W.S., Salajegheh, M., Praestgaard, J., et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83:24 (2014), 2239–2246.
9. Amemiya, K., Granger, R.P., Dalakas, M.C., Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 123 (2000), 2030–2039.
10. Askanas, V., Engel, W.K., Nogalska, A., Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta 1852:4 (2015), 633–643.
11. Badrising, U.A., Maat-Schieman, M., van Duinen, S.G., Breedveld, F., van Doorn, P., van Engelen, B., et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 55:9 (2000), 1385–1387.
12. Barkhaus, P.E., Periquet, M.I., Nandedkar, S.D., Quantitative electrophysiologic studies in sporadic inclusion body myositis. Muscle Nerve 22:4 (1999), 480–487.
13. Barohn, R.J., Herbelin, L., Kissel, J.T., King, W., McVey, A.L., Saperstein, D.S., et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 66:2 Suppl. 1 (2006), S123–S124.
14. Benveniste, O., Hilton-Jones, D., International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 20:6 (2010), 414–421.
15. Benveniste, O., Guiguet, M., Freebody, J., Dubourg, O., Squier, W., Maisonobe, T., et al. Long-term observational study of sporadic inclusion body myositis. Brain 134 (2011), 3176–3184.
16. Bernhardt, K.A., Oh, T.H., Kaufman, K.R., Gait patterns of patients with inclusion body myositis. Gait Posture 33:3 (2011), 442–446.
17. Beyenburg, S., Zierz, S., Jerusalem, F., Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Investig 71:5 (1993), 351–361.
18. Brady, S., Squier, W., Hilton-Jones, D., Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 84:11 (2013), 1240–1246.
19. Brady, S., Squier, W., Sewry, C., Hanna, M., Hilton-Jones, D., Holton, J.L., A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open, 4(4), 2014, e004552.
20. Brannagan, T.H., Hays, A.P., Lange, D.J., Trojaborg, W., The role of quantitative electromyography in inclusion body myositis. J Neurol Neurosurg Psychiatry 63:6 (1997), 776–779.
21. Breithaupt, M., Schmidt, J., Update on treatment of inclusion body myositis. Curr Rheumatol Rep, 15(5), 2013, 329.
22. Broccolini, A., Mirabella, M., Hereditary inclusion-body myopathies. Biochim Biophys Acta 1852:4 (2015), 644–650.
23. Caballero, P.E., Candela, M.S., Alvarez, C.I., Tejerina, A.A., Chronic progressive external ophthalmoplegia: a report of 6 cases and a review of the literature. Neurologist 13:1 (2007), 33–36.
24. Cai, H., Yabe, I., Sato, K., Kano, T., Nakamura, M., Hozen, H., et al. Clinical, pathological, and genetic mutation analysis of sporadic inclusion body myositis in Japanese people. J Neurol 259:9 (2012), 1913–1922.
25. Chahin, N., Engel, A.G., Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:6 (2008), 418–424.
26. Chou, S.M., Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 86:6 (1968), 649–658.
27. Cordeiro de Souza, L., Campos, J.F., Daher, L.P., Furtado da Silva, P., Mechanical ventilation weaning in inclusion body myositis: feasibility of isokinetic inspiratory muscle training as an adjunct therapy. Case Rep Crit Care, 2014, 2014, 902541.
28. Cortese, A., Machado, P., Morrow, J., Dewar, L., Hiscock, A., Miller, A., et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord 23:5 (2013), 404–412.
29. Cox, F.M., Verschuuren, J.J., Verbist, B.M., Niks, E.H., Wintzen, A.R., Badrising, U.A., Detecting dysphagia in inclusion body myositis. J Neurol 256:12 (2009), 2009–2013.
30. Cox, F.M., Delgado, V., Verschuuren, J.J., Ballieux, B.E., Bax, J.J., Wintzen, A.R., et al. The heart in sporadic inclusion body myositis: a study in 51 patients. J Neurol 257:3 (2010), 447–451.
31. Cox, F.M., Reijnierse, M., van Rijswijk, C.S., Wintzen, A.R., Verschuuren, J.J., Badrising, U.A., Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 50:6 (2011), 1153–1161.
32. Cox, F.M., Titulaer, M.J., Sont, J.K., Wintzen, A.R., Verschuuren, J.J., Badrising, U.A., A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 134 (2011), 3167–3175.
33. Dabby, R., Lange, D.J., Trojaborg, W., Hays, A.P., Lovelace, R.E., Brannagan, T.H., et al. Inclusion body myositis mimicking motor neuron disease. Arch Neurol 58:8 (2001), 1253–1256.
34. D'Agostino, C., Nogalska, A., Engel, W.K., Askanas, V., In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol 37:3 (2011), 315–320.
35. Dalakas, M.C., Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 28:4 (2002), 779–798 vi.
36. Dalakas, M.C., Rakocevic, G., Schmidt, J., Salajegheh, M., McElroy, B., Harris-Love, M.O., et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132 (2009), 1536–1544.
37. Davenport, T.E., Benson, K., Baker, S., Gracey, C., Rakocevic, G., McElroy, B., et al. Lower extremity peak force and gait kinematics in individuals with inclusion body myositis. Arthritis Care Res (Hoboken) 67:1 (2015), 94–101.
38. Della Marca, G., Sancricca, C., Losurdo, A., Di Blasi, C., De Fino, C., Morosetti, R., et al. Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis. Clin Neurophysiol 124:8 (2013), 1615–1621.
39. Dimachkie, M.M., Barohn, R.J., Inclusion body myositis. Curr Neurol Neurosci Rep, 13(1), 2013, 321.
40. Dobloug, C., Walle-Hansen, R., Gran, J.T., Molberg, O., Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol 30:6 (2012), 838–842.
41. Dobloug, G.C., Antal, E.A., Sveberg, L., Garen, T., Bitter, H., Stjarne, J., et al. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study. Eur J Neurol, 22(4), 2015 672-e41.
42. Eisen, A., Berry, K., Gibson, G., Inclusion body myositis (IBM): myopathy or neuropathy?. Neurology 33:9 (1983), 1109–1114.
43. Eriksson, M., Lindberg, C., Hand function in 45 patients with sporadic inclusion body myositis. Occup Ther Int 19:2 (2012), 108–116.
44. Estephan, B., Barohn, R.J., Dimachkie, M.M., et al. Sporadic IBM: a case cohort. J Clin Neuromuscul Dis 12:3 (2011), 18–19.
45. Gang, Q., Bettencourt, C., Machado, P.M., Fox, Z., Brady, S., Healy, E., et al. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging 36:4 (2015), 1766.e1761–1766.e1763.
46. Ghosh, P.S., Laughlin, R.S., Engel, A.G., Inclusion-body myositis presenting with facial diplegia. Muscle Nerve 49:2 (2014), 287–289.
47. Goodman, B.P., Liewluck, T., Crum, B.A., Spinner, R.J., Camptocormia due to inclusion body myositis. J Clin Neuromuscul Dis 14:2 (2012), 78–81.
48. Greenberg, S.A., Biomarkers of inclusion body myositis. Curr Opin Rheumatol 25:6 (2013), 753–762.
49. Greenberg, S.A., Pinkus, J.L., Amato, A.A., Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 34:4 (2006), 406–416.
50. Griggs, R.C., Askanas, V., DiMauro, S., Engel, A., Karpati, G., Mendell, J.R., et al. Inclusion body myositis and myopathies. Ann Neurol 38:5 (1995), 705–713.
51. Herbert, M.K., Stammen-Vogelzangs, J., Verbeek, M.M., Rietveld, A., Lundberg, I.E., Chinoy, H., et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206691.
52. Hilton-Jones, D., Miller, A., Parton, M., Holton, J., Sewry, C., Hanna, M.G., Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 20:2 (2010), 142–147.
53. Hiniker, A., Daniels, B.H., Lee, H.S., Margeta, M., Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun, 1(1), 2013, 29.
54. Hiscock, A., Dewar, L., Parton, M., Machado, P., Hanna, M., Ramdharry, G., Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision. Physiotherapy 100:1 (2014), 61–65.
55. Hokkoku, K., Sonoo, M., Higashihara, M., Stalberg, E., Shimizu, T., Electromyographs of the flexor digitorum profundus muscle are useful for the diagnosis of inclusion body myositis. Muscle Nerve 46:2 (2012), 181–186.
56. Inamori, Y., Higuchi, I., Inoue, T., Sakiyama, Y., Hashiguchi, A., Higashi, K., et al. Inclusion body myositis coexisting with hypertrophic cardiomyopathy: an autopsy study. Neuromuscul Disord 22:8 (2012), 747–754.
57. Jackson, C.E., Barohn, R.J., Gronseth, G., Pandya, S., Herbelin, L., Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 37:4 (2008), 473–476.
58. Jethava, A., Ali, S., Dasanu, C.A., Primary respiratory failure due to inclusion body myositis: think outside the box. Conn Med 77:3 (2013), 155–158.
59. Johnson, L.G., Edwards, D.J., Walters, S., Thickbroom, G.W., Mastaglia, F.L., The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. Clin Neuromuscul Dis 8:4 (2007), 187–194.
60. Johnson, L.G., Collier, K.E., Edwards, D.J., Philippe, D.L., Eastwood, P.R., Walters, S.E., et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 10:4 (2009), 178–184.
61. Julien, J., Vital, C., Vallat, J.M., Lagueny, A., Sapina, D., Inclusion body myositis. Clinical, biological and ultrastructural study. J Neurol Sci 55:1 (1982), 15–24.
62. Khadilkar, S.V., Patil, S.G., Amin, S.N., Study of idiopathic inflammatory myopathies with special reference to borderland between idiopathic inflammatory myopathies and muscular dystrophies. Neurol India 56:3 (2008), 356–362.
63. Khurana, M.D., Luciano, C.A., Nerve conduction studies in inclusion body myositis observations in 63 patients 43rd Annual scientific meeting American Association of Electrodiagnostic Medicine. Muscle Nerve, 1996 43rd Annual scientific meeting American Association of Electrodiagnostic Medicine, Minneapolis, Minnesota.
64. Kosmidis, M.L., Alexopoulos, H., Tzioufas, A.G., Dalakas, M.C., The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci 334:1–2 (2013), 123–125.
65. Langdon, P.C., Mulcahy, K., Shepherd, K.L., Low, V.H., Mastaglia, F.L., Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature. Dysphagia 27:3 (2012), 408–417.
66. Larman, H.B., Salajegheh, M., Nazareno, R., Lam, T., Sauld, J., Steen, H., et al. Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 73:3 (2013), 408–418.
67. Lindberg, C., Oldfors, A., Prognosis and prognostic factors in sporadic inclusion body myositis. Acta Neurol Scand 125:5 (2012), 353–358.
68. Lindberg, C., Oldfors, A., Hedstrom, A., Inclusion body myositis: peripheral nerve involvement. Combined morphological and electrophysiological studies on peripheral nerves. J Neurol Sci 99:2–3 (1990), 327–338.
69. Lindberg, C., Persson, L., Bjorkander, J., Oldfors, A., Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scan 89:2 (1994), 123–131.
70. Lindberg, C., Trysberg, E., Tarkowski, A., Oldfors, A., Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 61:2 (2003), 260–262.
71. Lindberg, C., Klintberg, L., Oldfors, A., Raised troponin T in inclusion body myositis is common and serum levels are persistent over time. Neuromuscul Disord 16:8 (2006), 495–497.
72. Lloyd, T.E., Mammen, A.L., Amato, A.A., Weiss, M.D., Needham, M., Greenberg, S.A., Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology 83:5 (2014), 426–433.
73. Lotz, B., Engel, A., Nishino, H., et al. Inclusion body myositis. Observations in 40 patients. Brain 112:pt3 (1989), 727–747.
74. Lowes, L.P., Alfano, L., Viollet, L., Rosales, X.Q., Sahenk, Z., Kaspar, B.K., Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 45:2 (2012), 163–168.
75. Luciano, C.A., Dalakas, M.C., Inclusion body myositis: no evidence for a neurogenic component. Neurology 48:1 (1997), 29–33.
76. Ma, H., McEvoy, K.M., Milone, M., Sporadic inclusion body myositis presenting with severe camptocormia. J Clin Neurosci 20:11 (2013), 1628–1629.
77. Machado, P., Miller, A., Herbelin, L., He, J., Noel, J., Wang, Y., et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: a randomised, double-blind, placebo-controlled, phase IIA proof-of-concept trial. Ann Rheum Dis, 72(Suppl. 3), 2013, 164.
78. Maetzler, W., Reimold, M., Schittenhelm, J., Vorgerd, M., Bornemann, A., Kotter, I., et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry 82:9 (2011), 1060–1062.
79. Martin, S.E., Gondim, D.D., Hattab, E.M., Inclusion body myositis involving the diaphragm: report of a pathologically confirmed case. Neurol India 62:1 (2014), 66–67.
80. Mastaglia, F.L., Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol 28:2 (2009), 66–71.
81. Mastaglia, F.L., Needham, M., Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 22:1 (2015), 6–13.
82. Mastaglia, F.L., Needham, M., Scott, A., James, I., Zilko, P., Day, T., et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 19:11 (2009), 763–765.
83. Mastaglia, F.L., Rojana-udomsart, A., James, I., Needham, M., Day, T.J., Kiers, L., et al. Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul Disord 23:12 (2013), 969–974.
84. Mendell, J.R., Rodino-Klapac, L., Sahenk, Z., Malik, V., Kaspar, B.K., Walker, C.M., et al. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett 527:2 (2012), 90–99.
85. Muntzing, K., Lindberg, C., Moslemi, A.R., Oldfors, A., Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 58:2 (2003), 195–200.
86. Nakanishi, H., Koike, H., Matsuo, K., Tanaka, F., Noda, T., Fujikake, A., et al. Demographic features of Japanese patients with sporadic inclusion body myositis: a single-center referral experience. Intern Med 52:3 (2013), 333–337.
87. Needham, M., Mastaglia, F.L., Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6:7 (2007), 620–631.
88. Needham, M., Mastaglia, F.L., Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 18:1 (2008), 6–16.
89. Needham, M., Mastaglia, F.L., Garlepp, M.J., Genetics of inclusion-body myositis. Muscle Nerve 35:5 (2007), 549–561.
90. Needham, M., Corbett, A., Day, T., Christiansen, F., Fabian, V., Mastaglia, F.L., Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 15:12 (2008), 1350–1353.
91. Needham, M., Hooper, A., James, I., van Bockxmeer, F., Corbett, A., Day, T., et al. Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord 18:2 (2008), 150–152.
92. Needham, M., James, I., Corbett, A., Day, T., Christiansen, F., Phillips, B., et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 79:9 (2008), 1056–1060.
93. Nogalska, A., Terracciano, C., D'Agostino, C., King Engel, W., Askanas, V., P62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 118:3 (2009), 407–413.
94. Noto, Y., Shiga, K., Tsuji, Y., Kondo, M., Tokuda, T., Mizuno, T., et al. Contrasting echogenicity in flexor digitorum profundus-flexor carpi ulnaris: a diagnostic ultrasound pattern in sporadic inclusion body myositis. Muscle Nerve 49:5 (2014), 745–748.
95. Oflazer, P.S., Deymeer, F., Parman, Y., Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta Myol 30:1 (2011), 34–36.
96. Oh, S.J., Claussen, G.C., Single-fiber EMG findings in inclusion body myopathy. Muscle Nerve 18:9 (1995), 1031–1073 42nd Annual Scientific Meeting American Association of Electrodiagnostic Medicine, Montréal, Quebec, Canada, September 21–September 23, 1995.
97. Ozden, S., Gessain, A., Gout, O., Mikol, J., Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 32:3 (2001), 510–514.
98. Pars, K., Garde, N., Skripuletz, T., Pul, R., Dengler, R., Stangel, M., Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia. Muscle Nerve 48:5 (2013), 838–839.
99. Phillips, B.A., Cala, L.A., Thickbroom, G.W., Melsom, A., Zilko, P.J., Mastaglia, F.L., Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve 24:11 (2001), 1526–1534.
100. Pluk, H., van Hoeve, B.J., van Dooren, S.H., Stammen-Vogelzangs, J., van der Heijden, A., Schelhaas, H.J., et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol 73:3 (2013), 397–407.
101. Prutkin, J.M., Patton, K.K., Ventricular tachycardia in a patient with inclusion-body myositis. Pacing Clin Electrophysiol 32:12 (2009), e36–e39.
102. Rodriguez Cruz, P.M., Luo, Y.B., Miller, J., Junckerstorff, R.C., Mastaglia, F.L., Fabian, V., An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord 24:12 (2014), 1025–1035.
103. Rodriguez Cruz, P.M., Needham, M., Hollingsworth, P., Mastaglia, F.L., Hillman, D.R., Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. Neuromuscul Disord 24:12 (2014), 1036–1041.
104. Rojana-udomsart, A., Needham, M., Luo, Y.B., Fabian, V., Walters, S., Zilko, P.J., et al. The association of sporadic inclusion body myositis and Sjogren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 113:7 (2011), 559–563.
105. Rojana-udomsart, A., James, I., Castley, A., Needham, M., Scott, A., Day, T., et al. High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes. J Neuroimmunol 250:1–2 (2012), 77–82.
106. Rojana-udomsart, A., Mitrpant, C., James, I., Witt, C., Needham, M., Day, T., et al. Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC class II region in sporadic inclusion body myositis. J Neuroimmunol 254:1–2 (2013), 174–177.
107. Rose, M.R., 188th ENMC international workshop: inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 23:12 (2013), 1044–1055.
108. Rose, M.R., Jones, K., Leong, K., Walter, M.C., Miller, J., Dalakas, M.C., et al. Treatment for inclusion body myositis. Cochrane Database Syst Rev, 6, 2015 Cd001555.
109. Salajegheh, M., Pinkus, J.L., Taylor, J.P., Amato, A.A., Nazareno, R., Baloh, R.H., et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 40:1 (2009), 19–31.
110. Saltychev, M., Mikkelsson, M., Laimi, K., Medication of inclusion body myositis: a systematic review. Acta Neurol Scand, 2015, 10.1111/ane.12455.
111. Sekul, E.A., Chow, C., Dalakas, M.C., Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 48:4 (1997), 863–866.
112. Stubgen, J.P., Facioscapulohumeral muscular dystrophy. A quantitative electromyographic study. Electromyogr Clin Neurophysiol 47:3 (2007), 175–182.
113. Suzuki, N., Aoki, M., Mori-Yoshimura, M., Hayashi, Y.K., Nonaka, I., Nishino, I., Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 259:3 (2012), 554–556.
114. Takamure, M., Murata, K.Y., Kawahara, M., Ueno, S., Finger flexor weakness in inclusion body myositis. Neurology, 64(2), 2005, 389.
115. Tan, J.A., Roberts-Thomson, P.J., Blumbergs, P., Hakendorf, P., Cox, S.R., Limaye, V., Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 16:3 (2013), 331–338.
116. Tasca, G., Monforte, M., De Fino, C., Kley, R.A., Ricci, E., Mirabella, M., Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve, 2015, 10.1002/mus.24661.
117. Weihl, C.C., Baloh, R.H., Lee, Y., Chou, T.F., Pittman, S.K., Lopate, G., et al. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord 25:4 (2015), 289–296.
118. Wilson, F.C., Ytterberg, S.R., St Sauver, J.L., Reed, A.M., Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 35:3 (2008), 445–447.
119. Yunis, E.J., Samaha, F.J., Inclusion body myositis. Lab Invest 25:3 (1971), 240–248.